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Introduction
The association between hip fractures and an age-
related reduction in bone mass and quality was first 
recognised over 160 years ago by Sir Astley Cooper.1 It is 
estimated that one in two women and one in five men 
over the age of 50 years will sustain an osteoporotic 
fracture in their lifetime.2 The wrist, spine and hip are 
common fracture sites.
The global prevalence of hip fractures is rising. Of the 
global 9 million osteoporotic fractures that occurred in 
2000, 1.6 million were hip fractures.3 It is estimated that 
this number will increase to 2.6 million in 2025 and to 
6.3 million by the year 2050.4 While part of this increase 
can be explained by the worldwide increase in life 
expectancy, longevity alone does not entirely explain 
the increase, and several other factors, such as a 
decline in physical activity and increasing frailty, have 
been implicated.  
Fractures at the hip represent the most severe 
consequence of osteoporosis as they require admission 
and are associated with significant morbidity and 
mortality. In the first year following hip fractures, 20-24% 
of patients die, either owing to the fracture itself or to 
co-morbid disease. Fifty per cent are unable to walk 
without assistance and 33% are totally dependent or 
live in a nursing home. Mortality is significantly higher 
in men.
The combined annual cost of hip fractures was 
estimated to be €30 billion in the European Union and 
US$20 billion in the USA in 2002.5 Sixty-three per cent of 
the latter was for management of the hip fractures.6 
Drug therapy and hospital admissions further added 
to this expense.7 Fifteen years ago, the acute cost of 
treating a hip fracture in South Africa was estimated 
to be R50 000.8 Currently, it is approximately R150 000. 
Epidemiology of hip fractures
There are significant variations in hip fracture rates 
according to different geographic areas, and ethnic 
and gender groups.
Geographic and ethnic variations
The highest hip fracture rates, at greater than 6 per 
1 000 per year, are seen in the white Scandinavian and 
North American populations, followed by a rate of 4-6 
per 1 000 per year in England, Scotland, New Zealand 
and Finland.9 In Europe, the incident rate varies from the 
north, where it is highest, to lower rates in France and 
Switzerland. The lowest rates are in the Mediterranean 
countries.10 Intermediate fracture rates have been 
reported in Turkey, Kuwait and Iran, and the Asian 
communities of Singapore, Hong Kong and Japan.10-13 
The lowest rates have been described in developing 
countries and in black populations in Africa.     
There have been limited studies on osteoporotic fractures 
in Africa. In earlier studies, no minimal trauma fractures 
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were identified in rural Gambia,14 and an age-related 
increase in hip fractures was not observed in Nigeria.15 
However, in a more recent study from Cameroon, hip 
fractures were identified in 40 subjects (27 women and 
13 men) aged 50 years and above.16 Compared to the 
USA, the substantially lower fracture rate was attributed 
to the significantly lower life expectancy. Similarly, the 
lower incidence of osteoporotic fractures in Morocco 
has also been ascribed to a lower life expectancy.17 
However, these studies do show that osteoporotic 
fractures occur in Africa.
In South Africa, studies have examined risk factors 
and the prevalence of osteoporosis in the different 
ethnic groups. Until recently, there has been only one 
study on the prevalence of hip fractures. This study18 
reported an extremely low prevalence of hip fractures 
in black South Africans, which could not be explained 
by differences in bone mass. Bone mineral density 
(BMD) has been reported to be the same or higher in 
blacks than whites19, 20 and persons of mixed ancestry.21 
However, a recent study reported hip fractures in all 
ethnic groups in South Africa and supports clinical 
experience that hip fractures are more common than 
previously thought.22
While the incidence of hip fractures appears to 
be stabilising in the more developed countries, it is 
projected that the burden of osteoporotic hip fractures 
will shift to Latin American, Asia and Africa, where the 
population are rapidly ageing. It is predicted that in the 
year 2050, 70% of over 6-million predicted fractures will 
occur in these populations. 
Within countries, ethnic differences have also been 
reported in the incidence of hip fractures. In the USA, 
the age-adjusted incidence rates of hip fractures were 
higher in whites than Asians, blacks and Hispanics.23 
Higher bone mass and shorter hip-axis lengths in 
black and Hispanic populations may explain these 
differences.24 Similarly, differences in hip-axis length 
have also been suggested as a cause of the lower 
adjusted fracture rates in Indians than in Chinese 
and Malay subjects in Singapore.25 Other contributing 
factors for ethnic differences include variations in bone 
size, levels of physical activity, diet, neuromuscular 
functioning and frequency of falls.  
Age and gender
The exponential rise in the prevalence of osteoporotic 
hip fractures with advancing age is explained by 
the age-related decrease in bone strength and the 
increase in frequency of falls in the elderly, especially 
women. Over their lifetime, bone density at the femoral 
neck is estimated to decrease by 58% in women and 
39% in men, and by 53% and 35% at the proximal femur, 
in women and men respectively.26 
The female to male ratio of osteoporotic hip fractures 
in countries with a high incidence rate of osteoporosis 
is 2:1, but approaches 1:1 with advancing age27 
and in countries with a low hip fracture incidence.17 
Hip fractures generally occur at a later age in men, 
but regional differences have been reported. In an 
Australian study, the burden of hip fractures was shown 
to occur at an earlier age in men, than in women.28 
In this study, the incidence of fractures peaked at 
84 years in men. Forty-eight per cent experienced 
fractures before the age of 80 years, compared to 
66% of women who had fractures before the age of 
85 years.28 Analysts predict that by the year 2040, with 
increasing life expectancy in men, there will be as many 
hip fractures in men as there are in women today. 
Other risk factors for hip fractures
Numerous large epidemiological studies have identified 
risk factors for hip fractures. In addition to age, gender 
and ethnicity, these include: 
• Low BMD. 
• Frequency of falls.
• Prior fractures.
• Low bodyweight.
• Excessive alcohol intake and smoking.
• Cognitive impairment.
• Vitamin D deficiency or insufficiency. 
• Secondary causes of osteoporosis.
BMD is one of the most important determinants of 
fracture. Although geometry, micro-architectural 
integrity, length and cross-section of the proximal 
femur all contribute to bone strength, the relationship 
between BMD and fracture has been best established. 
For every one standard deviation decrease in BMD, 
there is a 2.4 to threefold increase in age-adjusted hip 
fractures.29 The existence of a prevalent fracture is also 
a strong predictor of future hip fractures. The presence 
of a prior distal arm or vertebral fracture has been 
shown to increase the risk of hip fractures30, 31 and a 
person with one hip fracture has a 60% increased risk of 
having a subsequent hip fracture.32 Previous childhood 
fractures and a maternal history of hip fractures are 
also strongly associated with increased risk.33
Almost all hip fractures are preceded by a fall. 
Important risk factors for falls include advanced age, 
frailty, cognitive impairment, postural hypotension, 
visual, gait and balance disturbances, use of drugs 
such as sedatives and alcohol, and environmental 
hazards.34
The World Health Organization recognised that clinical 
risk factors increase risk fractures independently of 
BMD, and that the risk of fracture increases with the 
number of risk factors present. It developed a fracture 
risk assessment tool called FRAX®.35 This tool integrates 
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the risk associated with clinical risk factors that were 
identified from meta-analyses of large epidemiological 
studies, as well as BMD at the femoral neck, to 
calculate the 10-year probability of fractures for men 
and women. The FRAX® score improves the prediction 
of future fractures. However, the derived intervention 
thresholds are dependent on epidemiological and 
health economic data, and are therefore country-
specific. While a study is underway, there are no 
available incidence data on hip fractures in South 
Africa. Consequently, the FRAX® cannot be applied to 
South African populations at present. 
Morbidity and mortality post hip fractures
Osteoporotic hip fractures account for more disability-
adjusted life years (DALYs) than most cancers, asthma 
and rheumatoid arthritis.3 Up to 50% of patients have 
permanent disability post a hip fracture, and only 30% 
regain full function. One year post a hip fracture, 40% 
of patients are unable to walk independently, 60% 
require assistance with one essential daily living activity 
(such as dressing), and 80% require assistance with 
at least one instrumental daily living activity (such as 
shopping).36 
Globally, there is a 10-20% mortality rate following hip 
fractures. Mortality and morbidity rates increase with 
increasing age, the presence of co-existing diseases 
and poor functional status prior to the fracture. 
Mortality is highest within the first six months, and relates 
to the fracture itself, whereas after six months, it is more 
likely to be due to pre-existing diseases and functional 
status.37 In a prospective study in Britain, the mortality 
rate post hip fracture was 33% at 12 months, and 15% of 
patients died in hospital prior to discharge.38
Predictors of mortality
A higher mortality rate has been reported in men than in 
women. In one study, 14% of men died in hospital in the 
immediate period following a hip fracture, compared 
to 6% of women.39 Hospital stay is also longer for men 
and days spent in hospital by men for osteoporotic hip 
fractures exceed those for carcinoma of the prostate.27 
Strong evidence of 12 predictors of mortality was 
reported following a recent large meta-analysis of 64 
316 patients, where overall in-patient or one-month 
mortality was 13.3%, and 15.8%, 24.5% and 34.5% at 3-6 
months, one year and two years, respectively.40 The 
predictors were advanced age, male gender, nursing 
home or facility residence, poor preoperative walking 
capacity, poor daily living activities, poorer global 
physical status and fitness for surgery (as defined by a 
higher American Society of Anesthesiologists grading), 
poor mental state, multiple co-morbidities, dementia or 
cognitive impairment, diabetes, cancer and cardiac 
disease.41 Other studies have also identified low 
albumin levels on admission and a delay in surgery as 
predictors of a poor outcome.42
Acute management of hip fractures
Patients who sustain hip fractures are usually of 
advanced age with multiple co-morbidities and 
are therefore at high risk of peri- and postoperative 
complications, which can be mitigated by appropriate 
pre- and postoperative management, ideally by a 
multidisciplinary team (Table I).
Timing of surgery
Timing of surgery refers to the time from the fracture 
to the time of surgical fixation. There is no consistent 
definition as to what constitutes early surgery, but 
most studies have used a period of between 24 and 
72 hours. (The International Osteoporosis Foundation 
(IOF) recommends 24 hours). In a meta-analysis of 16 
observational studies, earlier surgery was associated 
with a significantly lower mortality rate [relative risk (RR) 
0.81, 95% confidence interval (CI): 0.68-0.96, p-value = 
0.01]. Earlier surgery also significantly reduced in-hospital 
pneumonia (RR 0.59, 95% CI: 0.37-0.93, p-value = 0.02) 
and pressure sores (RR 0.48, 95% CI: 0.34-0.69, p-value 
< 0.001). By contrast, earlier surgery has not been shown 
to reduce the risk of deep venous thrombosis (DVT) or 
pulmonary embolism.42 
It is recommended that patients who are admitted 
with a hip fracture and who are medically fit should 
undergo surgical fracture management within 24 hours 
of fracture in non-after hours operating time (generally 
accepted as 08h00 to 20h00, seven days a week).43 
Delaying surgery for medical stabilisation
More than 60% of older patients who are admitted 
with a hip fracture will have significant co-existent 
medical pathology.44 Briefly delaying surgery, but still 
aiming for its occurrence within 72 hours post fracture, 
is recommended for the medically unstable patient to 
allow for maximal medical optimisation. 
Classes of major abnormalities associated with poor 
postoperative outcomes include: 45
•	 Cardiovascular	 disease: Cardiovascular disease 
encompasses systolic blood pressure < 90 mmHg, 
ventricular tachycardia or supraventricular tachy-
cardia (a rate > 120/minute), a third-degree heart 
block or heart rate of < 45/minute, a new myocardial 
infarction on electrocardiogram (ECG), or chest 
pain with an abnormal ECG, pulmonary oedema 
or heart failure confirmed on a chest X-ray.
•	 Respiratory	 conditions: These are defined by a 
temperature < 350C. (This emphasises the need 
for special low-reading thermometers in the 
trauma unit) or ≥ 38.50C plus a clinical diagnosis 
of pneumonia or chest infiltrates on radiograph, 
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respiratory failure with oxygen saturation of < 90% 
on pulse oximetry, or oxygen partial pressure (pO2) 
< 60 mmHg or carbon dioxide partial pressure 
(pCO2) of > 55 mmHg).
•	 Haematological	abnormalities: These are classified 
as an international normalised ratio > 1.6 and 
haemoglobin < 7.5 g/dl.
•	 Serum	electrolytes	and/or	 renal	abnormalities: This 
refers to sodium < 125 mmol/l or potassium < 2.5 
mmol/l, urea >18 mmol/l, creatinine > 225 μmol/l 
or serum glucose > 33 mmol/l. It is recommended 
that the aim should be a serum glucose level of 6-10 
mmol/l during the perioperative period.
Type of anaesthesia: regional (spinal or epidural) 
versus general
There is no evidence to support a preference for 
regional over general anaesthesia.46 On the contrary, 
the Scottish Hip Fracture Audit showed a very small, 
but statistically significant, lower absolute mortality 
in patients who received general versus regional 
anaesthesia.44
Managing cardiac risk: beta blockers, statins and 
anti-platelet agents
Death from cardiovascular disease occurs 90 times 
more commonly than that from fatal pulmonary 
embolism within the first six months of hip fracture.47
Cardioselective beta blockers
Orthopaedic surgery is considered to be intermediate 
risk surgery, with a reported risk of cardiac death 
or nonfatal myocardial infarction of up to 5%.48 The 
American College of Cardiology and the American 
Heart Association recommends that patients who are 
scheduled to undergo intermediate-risk surgery with 
more than one clinical risk factor should be treated 
with cardioselective beta blockers such as atenolol, 
bisoprolol and metoprolol, and that the dose should 
be titrated to achieve a heart rate between 60 and 80 
Table I: Recommendations for acute orthogeriatric fracture management in South Africa
Emergency department or casualty
• Emergency resuscitation should be carried out, if needed.
• A patient with a suspected hip fracture should receive an appropriate X-ray of the hip, pelvis and chest. 
• Intravenous fluids can be started.
• Blood should be sent for analysis. (This includes a full blood count, international normalised ratio/partial thromboplastin time, type 
and screen, urea, creatinine and electrolytes, and corrected calcium).
• An electrocardiograph must be carried out.
• Pain should be assessed at regular intervals, according to a standard pain treatment regimen.
• A urinary catheter needs to be placed, with drainage to gravity.
• Once the fracture has been confirmed, an urgent referral or transferral to a definitive orthopaedic service must be carried out.
• An associate geriatric physician team should be notified. 
• An initial orthopaedic assessment can be performed.
Preoperative management
• The patient can be admitted preferentially to a designated unit or ward. 
• Old records should be obtained as soon as possible.
• A physician or geriatrician assessment must be carried out, anaesthetics notified of the surgical plan and theatre booked. 
• Assessments or vital signs must be taken 4-6 hourly, including blood pressure, pulse, temperature, pain, pulse oximetry, orientation or 
confusion, as well as neurovascular checks. Intake and output should be monitored.
• Bed rest is important and should encompass two-hourly pressure care, including heel protectors, anti-embolic compression devices 
and use of pressure-relief mattresses and an overhead trapeze, if available.
• Foot and ankle exercises can be conducted every 1-2 hours, as well as incentive spirometry (sustained maximal inspiration with visual 
feedback on a spirometer) every hour when awake.
• An assessment should be made of cardiac and thrombotic risk and the need for a beta blocker and/or statin. 
• Team collaboration is important regarding anticoagulant (aspirin, warfarin or clopidogrel) issues.
• Low-molecular-weight heparins should be commenced, unless contraindicated.
• The standardised pain regimen should continue.
• A normal diet is allowed until six hours before surgery. Water, lemonade and clear carbohydrate-enriched drinks may be considered 
until two hours before surgery, if permitted by the anaesthetics’ team.
• An assessment should be carried out of nutritional status, and supplementation provided for patients with poor nutrition, or those who 
are at-risk of poor nutrition.
• A bowel regimen can be commenced.
• Deliriogenic medications, such as hypnotics, antihistamines, anticholinergics and benzodiazepines, should be avoided or withdrawn. 
Low-dose haloperidol prophylaxis should be considered for high-delirium-risk patients who have no contraindication to neuroleptics.
• Low-dose maintenance hypnotics can be contemplated in hypnotic-dependent patients.
• An antiemetic regimen should be started, if needed. 
• Continuous oxygen therapy can be implemented at 2 l/minute, or higher flows to keep saturations > 93%.
• Brochures may be handed over and discussions commenced with the patient and his or her family on hip fracture care, including 
aspects of rehabilitation and discharge planning.
• Cefazolin 1 g can be given preoperatively to nonallergic patients in the operating room.  
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beats per minute. Clinical risk factors include ischaemic 
heart disease, a history of congestive cardiac failure, 
a history of cerebrovascular disease, diabetes mellitus 
with insulin therapy and renal impairment. Extended 
release beta blockers should be avoided in these 
patients as they may increase the risk of sustained 
significant perioperative hypotension. Therapy should 
be continued for at least seven days postoperatively, 
unless the patient develops significant hypotension or 
bradycardia.49
Perioperative statins
Patients with established coronary artery or other 
vascular disease should be considered for statin 
use, if not already on statin therapy. A meta-analysis 
to determine the influence of statin treatment on 
adverse postoperative outcomes (including patients 
undergoing noncardiovascular surgery) showed a 
significant reduction in mortality and in acute coronary 
syndromes in patients taking statins.50 Patients who 
are already taking statins should continue this therapy 
during the perioperative period. However, presently 
Table I: Recommendations for acute orthogeriatric fracture management in South Africa cont.
Postoperative management
• The patient should be seen daily by the orthopaedic surgeon and a physician or geriatrician, with frequent communication between 
the teams.
• The patient can then be started on clear fluids and the diet advanced, according to tolerance. The diet should include additional 
supplementation for malnourished or at-risk patients. Dentures must be used properly, and patients properly positioned for and 
assisted with meals, if necessary.
• Oxygen therapy can be implemented through a nasal catheter when the patient is resting and during the first four nights 
postoperatively. The patient should turn, cough and breathe deeply every 1-2 hours, while awake.
• Transfusion may take place to keep the haemoglobin > 10 g/dl.
• Prophylactic antibiotics can be continued for 24 hours postoperatively (cefazolin 1 g eight-hourly).
• An assessment should be made of the patient’s vital signs 4-6 hourly, including blood pressure, pulse, temperature, pain, pulse 
oximetry, orientation and confusion, as well as neurovascular checks. Intake and output must also be monitored.
• The standardised pain regimen can be continued.
• Anticoagulation should be continued or commenced with unfractionated or a low-molecular-weight heparin, and the dose adjusted 
according to renal function. The duration of the anticoagulation will need to be individualised and may be from 2-6 weeks.
• The bowel regimen must be continued, with the aim for a bowel movement by postoperative day two and every 48 hours thereafter.
• The catheter may be removed by 10h00 on day one postoperatively. If retention is suspected, this should be confirmed using either an 
immediate ultrasound bladder scan or single catheterisation to measure the residual volume. (There is retention if there is > 300 ml). If 
a second episode of retention occurs, then scheduled intermittent catheterisation should either be sustained 4-6 hourly, or continuous 
catheterisation for 1-2 days. It is important to screen for and treat urinary tract infections. A skin care programme can be implemented 
for patients with established incontinence.
• Intake and output must be recorded to assess fluid balance.
• Activity should comprise the patient walking from the bed to the chair twice a day by day one postoperatively. Further activity is 
dependent on the patient’s weight-bearing status.
• Occupational and physiotherapy should be commenced on day one postoperatively. Pre-emptive analgesia is recommended 
before mobilisation takes place.
• Use of adaptive devices, such as glasses and hearing aids, should be ensured, as well as regular orientation.
• Calm reassurance, the family presence or a sitter should be used to assist with agitation.
• Appropriate postoperative surgical films can be ordered.
• Rehabilitation or social services consultation can take place for the purposes of discharge planning.
• An assessment of recurrent fall risk should be carried out and a fall prevention programme devised.
• Management, and additional investigation of the underlying cause, of established severe osteoporosis should be implemented. 
This must include vitamin D and calcium supplementation, as well as specific bone therapies. In-patient vitamin D repletion is 
recommended with three daily doses of 50 000 iu of calciferol, or a 150 000 iu loading dose of calciferol. Specific bone therapy 
should be commenced in stable patients within 48 hours of discharge. Detailed referral is necessary on discharge, including written 
instructions and follow-up arrangements.
Standard pain treatment regimen
• Paracetamol 1g, six-hourly orally or intravenously, should be given. 
• Tramadol is an intermediate-efficacy atypical opioid. Dose adjustment is necessary in older persons. Dosage is 50-100 mg intravenously 
or orally, at 12-hourly intervals.
• Morphine 5-10 mg can be used 4-6 hourly subcutaneously or intramuscularly, or sustained-release given orally, initially at 10 mg twice 
daily. Intravenous morphine should only be utilised in high care or intensive care settings. A naloxone injection must be immediately 
available if morphine is utilised.
• Nonsteroidal anti-inflammatories should only be given to non-frail patients (generally those who are younger than 75 years old), 
without cardiovascular co-morbidity, and who are haemodynamically stable with normal renal function. If necessary, ibuprofen 200-
400 mg eight-hourly can be considered. Regular monitoring of renal function and prophylactic anti-acid therapy with a proton-pump 
inhibitor is recommended. Intramuscular preparations should never be used.
• Dihydrocodeine is an intermediate-efficacy opioid. Doses of 30 mg should be given orally 4-6 hourly, or 50 mg intramuscularly or 
subcutaneously 4-6 hourly.
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there is not sufficient evidence to support the routine 
use of statin therapy for all patients undergoing hip-
fracture repair surgery.50
Anti-platelet agents
•	 Aspirin:	 Patients taking aspirin for cardiovascular 
risk reduction should continue therapy throughout 
the perioperative period as this benefit outweighs 
the risk of bleeding.51 Used alone, aspirin does not 
appear to increase the risk of spinal haematoma 
during regional anaesthesia.52 A meta-analysis 
of 10 orthopaedic trauma trials found that aspirin 
significantly reduced the rate of DVT and pulmonary 
embolism, compared with placebo. However, this 
reduction was significantly less when compared 
with other agents, such as warfarin and a low-
molecular-weight heparin.53
•	 Clopidogrel: The use of clopidogrel, either alone 
or in combination with aspirin, is associated with 
increased perioperative blood loss. This risk is further 
enhanced with a shorter time between the last dose 
and surgery and longer operative times.54 Patients 
taking clopidogrel require careful individualised 
assessment of perioperative bleeding risk versus the 
risk of vascular events. Options include delaying 
surgery for five days post clopidogrel cessation 
when the bleeding risk will be lower. However, the 
risks of thrombosis and immobility complications will 
be higher. Alternatively, surgery may be performed 
48 hours after cessation of clopidogrel, when 
although antiplatelet activity persists, active 
metabolites will have been cleared, allowing for 
platelet transfusion in the event of severe bleeding.55
•	 Warfarin:	 Rapid correction of warfarin anticoag-
ulation is possible with the use of fresh frozen plasma 
and vitamin K infusion. Ongoing perioperative 
anticoagulation, with either unfractionated or a 
low-molecular-weight heparin, is recommended for 
high-risk patients, e.g. patients with metal prosthetic 
heart valves.
Prevention of deep vein thrombosis and pulmonary 
thromboembolic disease
The prevalence of DVT in patients with hip fractures 
is as high as 40-60%. The risk occurs from the time of 
fracture. Mechanical pumping devices may protect 
against DVT. Handoll et al reported a significantly 
lower prevalence of DVT in patients when mechanical 
pumping devices were used, than when they were not 
(7% vs. 22%, RR 0.31, 95% CI: 0.19-0.51). Problems with 
skin abrasion and compliance have been reported.56
Prophylaxis, with an unfractionated heparin or a low-
molecular-weight heparin, has been shown to reduce 
the incidence of lower-limb DVT (26% vs. 42%, RR 0.60, 
95% CI: 0.50-0.71). There was no mortality difference 
between treatment and placebo. There is insufficient 
evidence to establish if low-molecular-weight heparins 
are superior to unfractionated heparins in the acute 
hip-fracture setting.57 Excessive bleeding, or the need 
for transfusion, is significantly increased (6% vs. 3.8%) 
with the use of subcutaneous heparin prophylaxis.58 
Prospective large-scale observational cohort studies 
from France and Norway show that the use of heparin 
prophylaxis reduces the incidence of DVT to 1.3-2.7%, 
and that of pulmonary embolism to 0.25-1.7%.47,59 
Nutrition
All patients should undergo an assessment of nutritional 
status on admission, using validated bedside nutritional 
tools, such as the Mini-Nutritional Assessment®,60 or 
an assessment by a dietitian. Measures to alleviate 
poor food intake during hospital admission aim to 
prevent malnutrition which may hinder recovery. One 
systematic review has found that oral protein and 
energy feeds reduced unfavourable outcomes after 
surgery for a hip fracture.61
Perioperative antibiotics
Perioperative antibiotics, either single- or multiple-dose 
regimens (Table I), reduce the incidence of deep 
wound, superficial wound, urinary tract and respiratory 
tract infections. Adverse effects, such as an allergy, 
rash or gastrointestinal complaints, are rare (< 2%). 62 
Delirium
Delirium is an acute brain failure syndrome or confusional 
state. It is associated with acute hip fractures, as both 
a potential contributor to sustaining the fracture, as 
well as a complication of the physiological stress of 
the fracture, its surgical repair and the associated 
hospital care and environment. Delirium occurs in 35-
65% of patients with hip fractures and is associated with 
adverse outcomes, high morbidity and mortality, longer 
length of hospital stay, greater functional decline and 
a high rate of institutionalisation after discharge.63-65 
Risk factors for delirium in patients with hip fractures 
include visual impairment, severe illness, pre-existing 
cognitive impairment, use of anticholinergic drugs, 
dehydration, perioperative blood pressure falls and 
infection.64 Proactive geriatric or physician consultation 
to facilitate multicomponent nonpharmacological 
interventions, i.e. multidisciplinary interventions which 
integrate supportive, environmental, nursing and other 
components of care, have been shown to reduce both 
delirium incidence (by over one third), and severity 
(severe delirium was reduced by over a half) in older 
in-patients.66, 67 Specific pharmacological therapy with 
low-dose (1.5 mg daily) haloperidol prophylaxis in high-
risk, older patients undergoing hip surgery was shown 
to significantly reduce the severity and duration (by 
6.4 days, 95% CI: 4-8 days), but not the incidence of 
postoperative delirium. No haloperidol-related side-
effects were noted in this double-blind, placebo-
controlled randomised trial with 430 participants.68 
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Pressure sores
Measures to prevent the development of pressure sores 
should commence from the time of fracture. High-
specification foam mattresses and pressure-relieving 
mattresses on operating tables prevent pressure sores 
(RR 0.29, 95% CI: 0.19-0.43).62 Earlier surgery also reduces 
pressure sores.42
Urinary retention
Older patients with hip fractures have a high risk of 
urinary retention (80% pre- and 50% post-surgery). Risk 
factors for urinary retention include advanced age, 
spinal anaesthesia, delirium, immobility, a previous 
history of bladder problems, prostatic hyperplasia, 
urethral strictures, pain, large amount of intravenous 
fluids, surgery of a long duration, longstanding diabetes 
(> 15 years), and use of anticholinergic medications 
and analgesics, and constipation. General evidence 
supports the removal of urinary catheters within 24 
hours postoperatively with a programme to detect 
and then prevent retention. Should retention develop, 
short-duration urethral catheterisation or scheduled 
intermittent catheterisation is recommended. This 
programme reduces the 25% rate of urinary tract 
infection that is associated with hip fracture.69
Pain control
Uncontrolled pain is a major impediment to 
postoperative functional recovery and is associated 
with longer hospital admission, more complications 
(such as delirium), a delay in ambulation, impaired 
functional recovery and greater suffering. Multi-
component intervention, including pain assessment, 
protocols for standing analgesia and pre-emptive 
analgesia before physiotherapy, has been shown to 
improve postoperative pain, reduce chronic pain and 
improve function. The multi-component intervention 
also results in a small but significant reduction in hospital 
stay duration.70 
Recommended analgesic agents for the management 
of hip-fracture-associated pain include opioids, 
weaker opioids, paracetamol and nonsteroidal anti-
inflammatory drugs (NSAIDs). Prescribers need to be 
cognisant of the higher risk of adverse drug events in 
frail older persons. 
Specific care regarding use of NSAIDs is required to avoid 
normotensive ischaemic renal failure. NSAIDs should be 
avoided in high-risk patients who have one or more of 
the following risk factors: older age (> 75 years), chronic 
renal disease, atherosclerosis, chronic hypertension, 
sepsis, perioperative hypotension, dehydration, 
excessive bleeding, heart failure, cardiac arrhythmias 
and concomitant use of angiotensin-receptor blockers 
or angiotensin-converting enzyme inhibitors.71 There is 
also concern from animal and retrospective studies 
that NSAIDs may delay fracture healing. However, this 
is controversial and one randomised controlled trial 
has shown no delay in fracture healing in patients who 
were given an NSAID.72
Use of femoral nerve blocks is advocated in some hip-
fracture programmes.73 Experience with this technique 
in the South African setting is limited.
Pharmacological therapy for osteoporosis in 
patients with post hip fractures
It is well established that a prior fracture increases 
the risk of subsequent fractures.74, 75 Importantly, the 
interval between fractures, even after a hip fracture, 
for those who survive, generally warrants intervention 
and treatment in order to reduce the risk of subsequent 
fracture.76,77 Despite this, osteoporosis is seldom 
diagnosed, investigated or treated in patients after 
a hip fracture.78, 79 The figure is as low as 10% in most 
studies.
Historically, the diagnosis of osteoporosis and even the 
therapeutic threshold, has been based on BMD criteria 
with a T-score of ≤ -2.5 considered to be diagnostic of 
osteoporosis. However, approximately 50% of patients 
who present with a hip fracture do not satisfy this 
criterion. This can partly be explained by the fact that 
98% of hip fractures occur following a fall. Therefore, the 
risk of fracture is determined by bone strength, the risk 
of falling and other factors. Prevention of subsequent 
fractures, in particular at the hip and nonvertebral 
sites, is best achieved by interventions which focus 
on strengthening bone, as well as those that aim to 
reduce the risk of falls.
Elderly patients with a prevalent fracture should 
receive treatment for osteoporosis regardless of the 
BMD. Therefore, all patients who survive a hip fracture 
should receive treatment to reduce future fracture risk. 
Unfortunately, this is rarely the case in the elderly who 
are the most frail and who are at the greatest risk.
Protein supplementation
Intervention studies, where protein intake was 
normalised by nasogastric feeding, parenteral nutrition 
or even oral dietary supplements, have reported an 
improved outcome after hip fracture. A daily oral 
protein supplement of 0.8 g/kg bodyweight has been 
shown to improve rehabilitation outcomes and reduce 
the risk of complications such as bed sores, anaemia, 
and respiratory and renal infections.80,81 This simple 
intervention reduced the total length of stay in hospital 
and rehabilitation units by 25% in patients who received 
protein supplementation compared to controls.  
Calcium and vitamin D
Calcium and vitamin D are essential for bone throughout 
life. Deficiencies are common in the elderly, and 
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especially in the institutionalised and frail elderly, and 
in patients presenting with hip fractures.82,83 Adequate 
calcium and vitamin D intake, in the elderly in particular, 
will prevent secondary hyperparathyroidism, maintain 
bone mass and architecture, improve muscle strength 
and reduce fracture risk. Therefore, vitamin D and 
calcium supplementation is a simple and inexpensive 
method of improving bone strength and reducing the 
risk of falling.
In a meta-analysis of double-blind studies of vitamin 
D supplementation with or without calcium, high-
dose vitamin D (800 IU per day) reduced the risk 
of falls by 19%, and by 23% when vitamin D levels of 
> 60 nmol/l were achieved.84 Calcium and vitamin 
D supplementation has also been shown to reduce 
the risk of falls and fractures in elderly women (with 
a mean age of 81 years) with a recent hip fracture.85 
The relative risk of fracture was also reduced by 43% 
and 32% at hip and nonvertebral sites, respectively, 
in ambulatory institutionalised women (mean age 84 
years) with severe calcium and vitamin D deficiency, 
after 18 months treatment with calcium 1 200 mg/day 
and vitamin D 800 IU/day, in a randomised, placebo-
controlled study. The hip and nonvertebral fracture risk 
was reduced by 29% and 24%, respectively, after 36 
months.86, 87
Supplementation of calcium and vitamin D in 
community living persons has shown smaller reductions 
in fracture risk. However, the baseline deficiencies 
of calcium and vitamin D in these subjects were less 
severe.88, 89 Three other community-based studies have 
shown no reduction in fracture risk in this population.90-92 
These conflicting results are likely to be the consequence 
of targeting low-risk populations of younger women 
who did not have baseline deficiencies of calcium and 
vitamin D.
Based on the available evidence, calcium and vitamin 
D should be supplemented in patients with known 
deficiency or those who are at high risk of insufficiency, 
using the correct dose and regimen. Patients who are 
in hospital after a hip fracture represent an extremely 
high-risk group and routine supplementation of calcium 
and vitamin D would be appropriate.
The recently published National Osteoporosis 
Foundation of South Africa (NOFSA) guidelines suggest 
a dose of vitamin D 800-1000 IU/day and calcium 1 000-
1 200mg/day (a dose which is considered to be safe).8 
Meta-analyses indicate that a dose of 800 IU vitamin D 
is required for optimal benefit in terms of preventing falls 
and reducing fracture risk.93 In addition, it is important 
to combine vitamin D with calcium in order to maximise 
outcomes post hip fracture, especially in elderly 
patients.94 Compliance with calcium and vitamin 
D is essential to maintain benefit. Compliance is a 
challenge in this population. Clinicians should focus the 
same degree of energy that they would to maximise 
compliance with any other chronic medication. 
Anti-osteoporosis medication
Several therapies, currently available in South Africa, 
have been proved in well-designed, placebo-
controlled studies to increase bone strength and 
reduce fracture risk in postmenopausal women. Limited 
fracture data are available on men with osteoporosis, 
although BMD responses in men to the bisphosphonates, 
teriparitide and strontium ranelate have been similar 
to those observed in women. Studies on zoledronate 
and strontium ranelate to determine fracture reduction 
in men are currently underway. There has been only 
one trial on fracture reduction in patients who have 
recently suffered a hip fracture. Most other randomised 
controlled trials have included a small percentage of 
elderly patients only; the population that is most at risk 
of sustaining a hip fracture. It is also least likely for anti-
osteoporosis medication to be initiated in the elderly. 
Data from the USA National Health and Nutrition 
Examination Survey (NHANES) showed that only 12% 
of women > 85 years who had a history of fracture 
received medication for osteoporosis.95
Bisphosphonates
The efficacy of bisphosphonates (alendronate, rise-
dronate and zoledronate) in preventing bone loss and 
reducing fracture risk is well established from large, 
randomised, placebo-controlled studies. However, 
limited data are available on elderly patients and 
patients who have experienced a hip fracture and 
those with osteopenia, as opposed to that on patients 
with osteoporosis following BMD measurement. 
However, limited data are available on elderly patients, 
patients with hip fractures, and those who have been 
diagnosed with osteopenia rather than osteoporosis on 
BMD measurement.
In a post hoc analysis of the Fracture Intervention Trial 
(FIT), there was a 38% reduction in vertebral fracture 
risk in women > 75 years who were treated with 
alendronate for three years.96 There are no data for 
patients > 80 years.  
Risedronate had no significant effect in preventing hip 
fractures in a subgroup of women aged > 80 years and 
recruited according to clinical risk factors only without 
a BMD diagnosis of osteoporosis, in the Hip Intervention 
Program Study Group.97 In a pooled analysis from three 
clinical studies, risedronate reduced the risk of vertebral 
fracture by 44% after three years in women > 80 years, 
but had no effect on nonvertebral fractures.98
In a retrospective analysis of 20 664 patients with hip 
fracture, little benefit of antiresorptive agents in the 
prevention of hip fractures was seen in patients > 80 
years, compared to those < 80 years (hazard ratio of 
0.92 vs. 0.53).99 These findings need to be interpreted 
with caution, as there was no suggestion of blunting 
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of treatment efficacy with age in the randomised 
controlled trials of bisphosphonates. However, the 
overall numbers of patients > 80 years were extremely 
low.
Evidence which supports the treatment efficacy of 
bisphosphonates in older patients post hip fractures 
is provided from the Health Outcomes and Reduced 
Incidence with Zoledronic Acid Once Yearly Recurrent 
Fracture Trial (HORIZON-RFT). A once-yearly infusion of 
zoledronate 5 mg significantly reduced the risk of both 
vertebral and nonvertebral fractures in patients with a 
mean age of 74.5 years with a recent hip fracture. The 
reduction in recurrent hip fractures was not significant, 
but the study was not powered to show this effect. In 
addition, zoledronate reduced the risk of death by 
28%. This highlights the impact of osteoporotic fractures 
on mortality in this very frail and high risk population.100 
In general, there is no apparent difference in the 
anti-fracture efficacy of the three bisphosphonates 
(alendronate, risedronate or zoledronate) that are 
registered for patients in this country. Therefore, no 
particular bisphosphonate is recommended. Until 
further safety and efficacy data become available, the 
use of generic bisphosphonates is not recommended.8 
There are also no convincing data to suggest that 
antiresorptives, such as the bisphosphonates, impair 
fracture healing.
Teriparitide
Teriparitide is an anabolic bone agent that is 
administered by daily subcutaneous injection to 
patients with severe osteoporosis. Because of cost 
constraints, its use is limited to patients with severe 
osteoporosis as defined by a very low BMD, significant 
bone loss on treatment, and the presence of more 
than two vertebral fractures. A hip fracture is regarded 
as one of the most severe end-points of osteoporosis. A 
potent anabolic agent is an attractive option. Limited 
data on this agent are available. Teriparitide was shown 
to significantly reduce the risk of vertebral fractures by 
65% in women > 75 years in a subgroup analysis. This 
effect is similar to that observed in women < 75 years. 
No significant effect on nonvertebral fractures was 
recorded after a median treatment duration of 19 
months.101 There are no available data on patients > 80 
years and those post hip fractures.
There is mounting evidence that teriparatide 
significantly improves the healing of nonvertebral 
fractures (the long bones and pelvis). However, 
following a fracture, its routine administration cannot 
be recommended yet.
Strontium ranelate
Pre-planned pooling of patients > 80 years from two 
major randomised controlled trials on strontium ranelate 
[The Spinal Osteoporosis Therapeutic Intervention 
(SOTI) and The TReatment Of Peripheral OSteoporosis 
(TROPOS)] showed an increase in BMD, as well as a 
reduced risk for vertebral and nonvertebral fractures 
after 1.3 and 5 years. Vertebral fractures were reduced 
by 59% at one year, 32% at three years and 31% at five 
years; all highly significant. Significant reductions in 
nonvertebral fractures (which included hip fractures) 
by 41% at one year, 31% at three years and 26% at five 
years, were also noted. After three years, there was a 
nonsignificant 32% reduction in the risk of hip fracture in 
patients > 80 years. A statistically significant reduction 
in hip fracture of 43% was noted in a subset of women 
aged > 74 years (a mean age of 79.2 years), and who 
were at high risk of fracture based on BMD (T-score 
< -2.5). This effect continued for up to five years.102-104
No studies have been carried out on strontium 
ranelate in patients who have suffered a previous hip 
fracture. However, strontium ranelate is the only agent 
with documented efficacy against vertebral and 
nonvertebral fractures in women > 80 years. Fracture 
risk reduction has been documented within one year 
and sustained over five years, even in the very elderly. 
The safety profile of strontium ranelate in people 
> 80 years is favourable and similar to that observed in 
younger patients.
Choice of agent
Given the lack of comparative data, it is difficult to 
make specific, evidence-based recommendations 
pertaining to choice of an anti-osteoporotic agent 
for patients post hip fracture. NOFSA recommends 
a bisphosphonate or strontium ranelate as the first 
choice for postmenopausal osteoporosis. Based on the 
only available evidence (HORIZON-RFT), it would be 
prudent and convenient to offer all patients who have 
survived a hip fracture an infusion of zoledronic acid 
5 mg, in conjunction with adequate calcium and 
vitamin D. This can be repeated after one year, 
and again, after two years. Alternatively, an oral 
bisphosphonate or strontium ranelate could be 
considered. This would depend on several patient 
criteria, such as age. Strontium ranelate has been 
shown to be effective in patients > 80 years.8  However, 
strontium ranelate should be avoided in patients with 
prior DVT, or in those who are at high risk of DVT. 
Benefits of dedicated orthogeriatric fracture unit/hip 
fracture programmes
The acute orthogeriatric unit is a model which 
provides joint care by geriatricians and orthopaedic 
surgeons and includes immediate geriatric assessment, 
coordinated daily clinical care, combined ward 
rounds, joint planning of the surgical schedule, initial 
mobilisation and discharge date and destination 
(discharge planning). Protocol-driven geriatric-
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focused care is inherent in this model. It has been 
replicated in multiple (generally developed) countries, 
using the expertise of geriatricians. Most published 
studies confirm the benefits of this approach, which 
include reduced length of hospital stay, costs and 
time to surgery; lower readmission rates and in-patient 
complication rates such as pneumonia, urinary 
tract infections and confusion or delirium; functional 
improvement (short-term OR 2.33, 95% CI: 1.62-3.34), 
reduced mortality (long-term RR 0.77, 95% CI: 0.61-
0.96, numbers needed to treat: 21), and reduced risk 
of nursing home admission (RR 0.72, 95% CI: 0.56-0.91, 
numbers needed to treat: 14).71,105 -111 Patients with mild 
or moderate cognitive impairment may show the most 
benefit.109 It is likely that patients in a country such as 
South Africa would derive significant benefit from this 
approach. Given the shortage of geriatricians in this 
country, a physician who has an interest or experience 
in the field should be part of the multidisciplinary team.
Summary and conclusion
Hip fractures generally occur in older patients who 
often have multiple co-morbidities, and who are at 
high risk of adverse outcomes and of incurring high 
medical costs. Increased morbidity and mortality can 
be reduced by a structured acute management plan 
and appropriate control of the risk factors. Ideally, a 
team-based approach should be employed. Patients 
with hip fractures should be assessed to exclude a 
secondary cause of osteoporosis and considered 
for specific osteoporosis therapy to prevent the next 
fracture.  
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